Skip to main content
Top
Published in: Rheumatology International 3/2012

Open Access 01-03-2012 | Original Article

Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity

Authors: Pawel Mielnik, Hanna Chwalinska-Sadowska, Ewa Wiesik-Szewczyk, Wlodzimierz Maslinski, Marzena Olesinska

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39–57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P = 0.05, CI95% 0.4–331; and sTNF-R1 P = 0.031, CI95% 15.1–321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.
Literature
1.
go back to reference Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14–32PubMedCrossRef Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14–32PubMedCrossRef
2.
go back to reference Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S et al (2002) N.Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 14:917–924PubMedCrossRef Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S et al (2002) N.Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 14:917–924PubMedCrossRef
3.
go back to reference Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H (2001) Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 28:2389–2391PubMed Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H (2001) Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 28:2389–2391PubMed
4.
go back to reference Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D (2000) Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19:101–105PubMedCrossRef Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D (2000) Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19:101–105PubMedCrossRef
5.
go back to reference Chrobak L, Podzimek K, Pliskova L, Kerekes Z, Zak P, Voglova J et al (1996) Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Neoplasma 43:321–325PubMed Chrobak L, Podzimek K, Pliskova L, Kerekes Z, Zak P, Voglova J et al (1996) Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Neoplasma 43:321–325PubMed
6.
go back to reference Samsonov MY, Nassonov EL, Tilz GP, Geht BM, Demel U, Gurkina GT et al (1997) Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Br J Rheumatol 36:656–660PubMedCrossRef Samsonov MY, Nassonov EL, Tilz GP, Geht BM, Demel U, Gurkina GT et al (1997) Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Br J Rheumatol 36:656–660PubMedCrossRef
7.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef
8.
go back to reference Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J et al (2002) Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 169:1760–1767PubMed Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J et al (2002) Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 169:1760–1767PubMed
9.
go back to reference Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61(S2):100–102 Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61(S2):100–102
10.
go back to reference Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J et al (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52:2686–2692PubMedCrossRef Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J et al (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52:2686–2692PubMedCrossRef
11.
go back to reference Horak P, Hermanova Z, Ordeltova M, Faltynek L, Kusa L, Budikova M et al (2004) Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes. Vnitr Lek 50:422–427PubMed Horak P, Hermanova Z, Ordeltova M, Faltynek L, Kusa L, Budikova M et al (2004) Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes. Vnitr Lek 50:422–427PubMed
12.
go back to reference Franczuk A, Szepietowski JC, Noworolska A (2004) Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: relationship with type and extent of the disease. Acta Dermatovenerol Croat 12:71–76PubMed Franczuk A, Szepietowski JC, Noworolska A (2004) Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: relationship with type and extent of the disease. Acta Dermatovenerol Croat 12:71–76PubMed
13.
go back to reference Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M et al (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford) 40:1398–1404CrossRef Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M et al (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford) 40:1398–1404CrossRef
14.
go back to reference Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359PubMedCrossRef Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359PubMedCrossRef
15.
go back to reference Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77:217–225PubMedCrossRef Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77:217–225PubMedCrossRef
16.
go back to reference Viac J, Vincent C, Palacio S, Schmitt D, Claudy A (1996) Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels. Eur J Cancer 32A:447–449PubMedCrossRef Viac J, Vincent C, Palacio S, Schmitt D, Claudy A (1996) Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels. Eur J Cancer 32A:447–449PubMedCrossRef
17.
go back to reference Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R (2003) Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumors. Anticancer Res 23:3057–3059PubMed Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R (2003) Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumors. Anticancer Res 23:3057–3059PubMed
18.
go back to reference Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesar V (2000) Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 6:661–667PubMed Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesar V (2000) Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 6:661–667PubMed
Metadata
Title
Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity
Authors
Pawel Mielnik
Hanna Chwalinska-Sadowska
Ewa Wiesik-Szewczyk
Wlodzimierz Maslinski
Marzena Olesinska
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1692-y

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue